AWS and Amgen Collaborate on Cutting-Edge Generative AI Solutions
Amazon Web Services has joined forces with pharmaceutical giant Amgen to leverage generative AI solutions for the accelerated development of advanced therapies. This collaboration marks a great step in the intersection of technology and life sciences. It aims to revolutionize medicine discovery, development, and manufacturing.
Amazon Web Services (AWS) is a cloud computing powerhouse offering a comprehensive suite of services to support various workloads. Established in 2006, AWS has become a global leader, providing solutions for computing, storage, databases, networking, analytics, machine learning, AI and more. Amgen is expanding its partnership with AWS to harness the power of generative AI in the quest for innovative therapies.
Digital and Robotic Technology
The upcoming facility will integrate cutting-edge digital and robotic technology, including a connected digital platform on AWS using Amazon SageMaker. This fully managed service will facilitate the collection and analysis of;
- manufacturing data
- reducing manual intervention
- enhancing safety
- predicting equipment failures in real-time
Such advancements are poised to unlock additional manufacturing capacity and decrease downtime. Mike Zahigian, Senior Vice President and Chief Information Officer at Amgen, expressed enthusiasm, stating,
“Our work with AWS over the last 10 years has helped us reinforce our data-driven approach, and working closely with AWS experts in machine learning and analytics allows us to move forward at an accelerated pace.”
Exploring the Potential of Generative AI and ML
Together, AWS and Amgen are actively experimenting with generative AI and machine learning (ML) technology across research and development, particularly in clinical trial innovation. Amazon Bedrock, a service offering foundation models via an API, and Amazon SageMaker JumpStart, an ML hub with pre-built solutions, play a crucial role in finding solutions for operations and commercial lines of business.
Dr. Matt Wood, Vice President of Technology at AWS, emphasizes the transformative potential of generative AI, stating,
“Combining AWS’s expansive capabilities and our 25 years of machine learning expertise with Amgen’s life sciences leadership and innovative culture, we are proud to work together to transform new ideas and discoveries into medicines that will improve treatment for patients with serious illnesses.”
In this era of digital transformation, the collaboration between AWS and Amgen stands as a beacon of progress, promising a future where generative AI plays a pivotal role in advancing healthcare and improving patient outcomes.
